PHARMA
Rheumatoide Arthritis: Die Hemmung der Januskinase als neues Therapieprinzip
Dtsch Arztebl 2012; 109(26): A-1389
| 1. | Kremer J, et al.: Tofacitinib (CP-690,550), an oral Janus Kinase Inhibitor: Analysis of efficacy endpoints by subgroups in a pooled phase 2 and 3 rheumatoide arthrtis study population. EULAR 2012: Poster THU0143. |
| 2. | Van Vollenhoven RF, et al.: Effects of Tofacitinib (CP-690,550), an oral Janus Kinase Inhibitor, or Adalimumab on patient reported outcomes in a phase 3 study of active rheumatoid arthritis. EULAR 2012: THU0151. |
